公开(公告)号：EP2421533A1

公开(公告)日：2012-02-29

申请号：EP10714825.6

申请日：2010-04-21

申请人： RESVERLOGIX CORP.

发明人： HANSEN, Henrik, C. ,  WAGNER, Gregory, S. ,  ATTWELL, Sarah, C. ,  MCLURE, Kevin, G. ,  KULIKOWSKI, Ewelina, B.

IPC分类号： A61K31/47 ,  C07D239/91

CPC分类号： A61K31/517 ,  A61K9/4833 ,  A61K31/47 ,  A61K31/5025 ,  C07D215/22 ,  C07D215/36 ,  C07D239/91 ,  C07D239/93 ,  C07D401/02 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D413/12 ,  C07D487/04

摘要： Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

摘要翻译： 公开了调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的方法以及治疗和/或预防心血管和炎性疾病以及相关疾病状态的方法，例如， 动脉粥样硬化，哮喘，关节炎，癌症，多发性硬化症，牛皮癣和炎症性肠病以及自身免疫性疾病，通过施用天然存在的或合成的喹唑啉酮衍生物。 本发明提供了新的合成喹唑啉酮化合物以及包含这些化合物的药物组合物。

公开(公告)号：EP2421533B1

公开(公告)日：2018-10-17

申请号：EP10714825.6

申请日：2010-04-21

申请人： Resverlogix Corp.

发明人： HANSEN, Henrik, C. ,  WAGNER, Gregory, S. ,  ATTWELL, Sarah, C. ,  MCLURE, Kevin, G. ,  KULIKOWSKI, Ewelina, B.

IPC分类号： A61K31/47 ,  C07D239/91

CPC分类号： A61K31/517 ,  A61K9/4833 ,  A61K31/47 ,  A61K31/5025 ,  C07D215/22 ,  C07D215/36 ,  C07D239/91 ,  C07D239/93 ,  C07D401/02 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D413/12 ,  C07D487/04

摘要： Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.